Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T.

Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Review.

PMID:
30738604
2.
3.

The ages of the cancer-associated genes.

Stein WD.

Semin Oncol. 2019 Feb;46(1):10-18. doi: 10.1053/j.seminoncol.2018.11.001. Epub 2018 Dec 7.

4.

Iron is a substrate of the Plasmodium falciparum chloroquine resistance transporter PfCRT in Xenopus oocytes.

Bakouh N, Bellanca S, Nyboer B, Moliner Cubel S, Karim Z, Sanchez CP, Stein WD, Planelles G, Lanzer M.

J Biol Chem. 2017 Sep 29;292(39):16109-16121. doi: 10.1074/jbc.M117.805200. Epub 2017 Aug 2.

5.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
6.

Time-of-flight Extreme Environment Diffractometer at the Helmholtz-Zentrum Berlin.

Prokhnenko O, Stein WD, Bleif HJ, Fromme M, Bartkowiak M, Wilpert T.

Rev Sci Instrum. 2015 Mar;86(3):033102. doi: 10.1063/1.4913656.

PMID:
25832206
7.

Multiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sites.

Bellanca S, Summers RL, Meyrath M, Dave A, Nash MN, Dittmer M, Sanchez CP, Stein WD, Martin RE, Lanzer M.

J Biol Chem. 2014 Dec 26;289(52):36336-51. doi: 10.1074/jbc.M114.614206. Epub 2014 Nov 6.

8.

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T.

Cancer Res. 2014 Sep 1;74(17):4653-62. doi: 10.1158/0008-5472.CAN-14-0420.

9.

A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparum.

Sanchez CP, Liu CH, Mayer S, Nurhasanah A, Cyrklaff M, Mu J, Ferdig MT, Stein WD, Lanzer M.

PLoS Genet. 2014 May 15;10(5):e1004382. doi: 10.1371/journal.pgen.1004382. eCollection 2014 May.

10.

Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporter.

Summers RL, Dave A, Dolstra TJ, Bellanca S, Marchetti RV, Nash MN, Richards SN, Goh V, Schenk RL, Stein WD, Kirk K, Sanchez CP, Lanzer M, Martin RE.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1759-67. doi: 10.1073/pnas.1322965111. Epub 2014 Apr 11.

11.

Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.

Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.

Cell Rep. 2013 Feb 21;3(2):277-81. doi: 10.1016/j.celrep.2013.01.015. Epub 2013 Feb 7.

12.

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.

Clin Cancer Res. 2012 Apr 15;18(8):2374-81. doi: 10.1158/1078-0432.CCR-11-2275. Epub 2012 Feb 17.

13.

Genetic linkage analyses redefine the roles of PfCRT and PfMDR1 in drug accumulation and susceptibility in Plasmodium falciparum.

Sanchez CP, Mayer S, Nurhasanah A, Stein WD, Lanzer M.

Mol Microbiol. 2011 Nov;82(4):865-78. doi: 10.1111/j.1365-2958.2011.07855.x. Epub 2011 Oct 18.

14.

The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.

Arnaud O, Boumendjel A, Gèze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A, Payen L.

Eur J Cancer. 2011 Mar;47(4):640-8. doi: 10.1016/j.ejca.2010.11.019. Epub 2011 Jan 7.

PMID:
21216589
15.

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.

Clin Cancer Res. 2011 Feb 15;17(4):907-17. doi: 10.1158/1078-0432.CCR-10-1762. Epub 2010 Nov 24.

16.

Genetic predisposition favors the acquisition of stable artemisinin resistance in malaria parasites.

Beez D, Sanchez CP, Stein WD, Lanzer M.

Antimicrob Agents Chemother. 2011 Jan;55(1):50-5. doi: 10.1128/AAC.00916-10. Epub 2010 Nov 1.

17.

Transporters as mediators of drug resistance in Plasmodium falciparum.

Sanchez CP, Dave A, Stein WD, Lanzer M.

Int J Parasitol. 2010 Aug 15;40(10):1109-18. doi: 10.1016/j.ijpara.2010.04.001. Epub 2010 Apr 24. Review.

PMID:
20399785
18.

Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.

Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE.

Cancer J. 2009 Sep-Oct;15(5):441-7. doi: 10.1097/PPO.0b013e3181be1b90. Review.

19.

Virulence and drug resistance in malaria parasites.

Stein WD, Sanchez CP, Lanzer M.

Trends Parasitol. 2009 Oct;25(10):441-3. doi: 10.1016/j.pt.2009.07.003. Epub 2009 Sep 4.

PMID:
19734096
20.

Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.

Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.

Oncologist. 2008 Oct;13(10):1046-54. doi: 10.1634/theoncologist.2008-0075. Epub 2008 Oct 6.

21.

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.

Stein WD, Yang J, Bates SE, Fojo T.

Oncologist. 2008 Oct;13(10):1055-62. doi: 10.1634/theoncologist.2008-0016. Epub 2008 Sep 30.

22.

Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum.

Sanchez CP, Rotmann A, Stein WD, Lanzer M.

Mol Microbiol. 2008 Nov;70(4):786-98. doi: 10.1111/j.1365-2958.2008.06413.x. Epub 2008 Aug 18.

23.

PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors.

Steadman K, Stein WD, Litman T, Yang SX, Abu-Asab M, Dutcher SK, Bates S.

Cell Cycle. 2008 Mar 15;7(6):818-29. Epub 2008 Jan 9.

PMID:
18239467
24.

Dissecting the components of quinine accumulation in Plasmodium falciparum.

Sanchez CP, Stein WD, Lanzer M.

Mol Microbiol. 2008 Mar;67(5):1081-93. doi: 10.1111/j.1365-2958.2008.06108.x. Epub 2008 Jan 10.

25.

Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum.

Sanchez CP, Stein WD, Lanzer M.

Trends Parasitol. 2007 Jul;23(7):332-9. Epub 2007 May 10. Review.

PMID:
17493873
26.

Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum.

Sanchez CP, Rohrbach P, McLean JE, Fidock DA, Stein WD, Lanzer M.

Mol Microbiol. 2007 Apr;64(2):407-20.

27.

A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients.

Stein WD, Litman T, Fojo T, Bates SE.

Biochim Biophys Acta. 2007 Jun;1770(6):857-71. Epub 2007 Jan 25.

PMID:
17398010
28.
29.
30.

A kinetic study of Rhodamine123 pumping by P-glycoprotein.

Wang Y, Hao D, Stein WD, Yang L.

Biochim Biophys Acta. 2006 Oct;1758(10):1671-6. Epub 2006 Jun 7.

31.

An ELISA-based procedure for assaying proteins in digests of human leukocytes and cell lines, using specifically selected peptides and appropriate antibodies.

Braitbard O, Bishara-Shieban J, Glickstein H, Kott-Gutkowski M, Pace U, Rund DG, Stein WD.

Proteome Sci. 2006 Jun 21;4:14. doi: 10.1186/1477-5956-4-14.

32.

Competition between bound and free peptides in an ELISA-based procedure that assays peptides derived from protein digests.

Braitbard O, Glickstein H, Bishara-Shieban J, Pace U, Stein WD.

Proteome Sci. 2006 May 31;4:12.

33.

Evidence for a pfcrt-associated chloroquine efflux system in the human malarial parasite Plasmodium falciparum.

Sanchez CP, McLean JE, Rohrbach P, Fidock DA, Stein WD, Lanzer M.

Biochemistry. 2005 Jul 26;44(29):9862-70.

PMID:
16026158
34.
35.

Differential expression of cell adhesion genes: implications for drug resistance.

Stein WD, Litman T, Fojo T, Bates SE.

Int J Cancer. 2005 Mar 1;113(6):861-5. Review.

36.

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.

Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.

Clin Cancer Res. 2004 Jul 15;10(14):4724-33.

37.

Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack.

Stein WD, Bates SE, Fojo T.

Curr Drug Targets. 2004 May;5(4):333-46. Review.

PMID:
15134216
40.

Pumping of drugs by P-glycoprotein: a two-step process?

Litman T, Skovsgaard T, Stein WD.

J Pharmacol Exp Ther. 2003 Dec;307(3):846-53. Epub 2003 Oct 8.

PMID:
14534356
41.

Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest.

Stein WD, Robey R, Cardarelli C, Gottesman MM, Bates SE.

Cell Cycle. 2003 Mar-Apr;2(2):134-42.

PMID:
12695665
42.

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC.

Clin Cancer Res. 2003 Feb;9(2):650-6.

43.

Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles.

Köhler S, Stein WD.

Biotechnol Bioeng. 2003 Mar 5;81(5):507-17.

PMID:
12514799
44.

Reversers of the multidrug resistance transporter P-glycoprotein.

Stein WD.

Curr Opin Investig Drugs. 2002 May;3(5):812-7. Review.

PMID:
12090558
45.
46.

Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine.

Hoshen MB, Stein WD, Ginsburg H.

Parasitology. 2002 Jan;124(Pt 1):9-15.

PMID:
11811806
47.

Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine.

Hoshen MB, Stein WD, Ginsburg HD.

Parasitology. 2001 Oct;123(Pt 4):337-46.

PMID:
11676365
48.

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

Litman T, Druley TE, Stein WD, Bates SE.

Cell Mol Life Sci. 2001 Jun;58(7):931-59. Review.

PMID:
11497241
49.
50.

Supplemental Content

Loading ...
Support Center